德生物科技公司BioNTech及輝瑞藥廠疫苗產生對抗新冠病毒細胞 免疫成效待檢測
德國生物科技公司BioNTech及美國輝瑞藥廠表示,雙方合作研發的新冠疫苗在初期測試結果良好。
於60名德國自願者測試中,測試者在接種兩劑疫苗後產生抗體,結果與在美國測試的相若。且測試亦顯示接種後產生高濃度對抗冠狀病毒的T細胞。分析認為T細胞為產生對新冠病毒免疫的關鍵因素。
測試未產生嚴重副作用,部分接種者出現類感冒徵狀。
另外,英國阿斯利康藥廠與牛津大學研發的疫苗顯示安全性及產生免疫反應,康希諾生物(06185.HK)及中國軍方研發的疫苗亦顯示類似結果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.